Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels.

Wilk, C Matthias; Kovtonyuk, Larisa V; Manz, Markus G

Wilk, C Matthias; Kovtonyuk, Larisa V; Manz, Markus G.

Afiliação

Wilk CM; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland.
Kovtonyuk LV; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland.
Manz MG; Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Comprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland.

Blood Adv ; 6(15): 4485-4489, 2022 08 09.

Article em En | MEDLINE | ID: mdl-35736667

Assuntos

Bussulfano; Transplante de Células-Tronco Hematopoéticas; Animais; Camundongos; Receptores Fc; Proteínas Recombinantes de Fusão; Trombopoetina/farmacologia; Trombopoetina/uso terapêutico; Condicionamento Pré-Transplante

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Bussulfano / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google